Page last updated: 2024-11-07

prednisone and Neuralgia

prednisone has been researched along with Neuralgia in 28 studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.

Research Excerpts

ExcerptRelevanceReference
"The effects of prednisone, oral acyclovir, and radiotherapy were compared with placebo in the prevention of post-herpetic neuralgia."9.07Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy. ( Allegra, F; Benoldi, D; Mirizzi, S; Zucchi, A, 1991)
" The patients received PTX at the initiating dosage until complete clinical cure."6.71[Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. ( Achirafi, A; de Carsalade, GY; Flageul, B, 2003)
"Central poststroke pain is a neuropathic pain syndrome that can occur from pathology of the brain."5.43A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. ( Batlle, L; Irwin, R; Mattie, R, 2016)
"The effects of prednisone, oral acyclovir, and radiotherapy were compared with placebo in the prevention of post-herpetic neuralgia."5.07Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy. ( Allegra, F; Benoldi, D; Mirizzi, S; Zucchi, A, 1991)
" We encountered severe autonomic neuropathy and cholestasis in a child receiving vincristine, after the introduction of piperacillin-tazobactam."3.78A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions? ( Andres, CR; Benz-de Bretagne, I; Gendrot, C; Jonville-Bera, AP; Jourdain, A; Le Guellec, C; Tarfaoui, N, 2012)
"Eighty-eight eligible patients with Hodgkin lymphoma stage I and II (<3 nodal sites, no B symptoms, mediastinal bulk, or extranodal extension) enrolled between March 3, 2000, and December 9, 2008."2.77Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. ( Billett, AL; Billups, CA; Donaldson, SS; Friedmann, A; Howard, SC; Hudson, MM; Krasin, MJ; Kun, LE; Larsen, EC; Link, MP; Marcus, KJ; Metzger, ML; Tarbell, N; Weinstein, HJ; Wu, J; Yock, TI, 2012)
" The patients received PTX at the initiating dosage until complete clinical cure."2.71[Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. ( Achirafi, A; de Carsalade, GY; Flageul, B, 2003)
"Central poststroke pain is a neuropathic pain syndrome that can occur from pathology of the brain."1.43A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. ( Batlle, L; Irwin, R; Mattie, R, 2016)
"Although occipital neuralgia is usually caused by degenerative arthropathy, nearly 20 other aetiologies may lead to this condition."1.42Idiopathic hypertrophic pachymeningitis presenting with occipital neuralgia. ( Auboire, L; Bienvenu, B; Boutemy, J; Busson, P; Constans, JM; Le Gallou, T, 2015)
"A rare cause of trigeminal neuralgia is malignant lymphoma which spread along the trigeminal nerve."1.40[Malignant lymphoma in a perineural spreading along trigeminal nerve, which developed as trigeminal neuralgia]. ( Arakawa, T; Kobayashi, Y; Mano, T; Matsuo, K; Ozawa, H, 2014)
"All patients had acute onset neuropathic pain, normal nerve conduction studies, and evidence of small-fiber dysfunction in quantitative sensory testing and skin biopsy."1.33Acute steroid responsive small-fiber sensory neuropathy: a new entity? ( Dabby, R; Gilad, R; Lampl, Y; Sadeh, M; Watemberg, N, 2006)
"Herpes zoster is a common disease which is frequently followed by severe long-term pain--post-herpetic neuralgia."1.27Should we treat herpes zoster with corticosteroid agents? ( Dickinson, JA, 1986)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-199015 (53.57)18.7374
1990's2 (7.14)18.2507
2000's4 (14.29)29.6817
2010's7 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Oerlemans, S1
Issa, DE1
van den Broek, EC1
Nijziel, MR1
Coebergh, JW1
Huijgens, PC1
Mols, F1
van de Poll-Franse, LV1
Mano, T1
Matsuo, K1
Kobayashi, Y2
Ozawa, H1
Arakawa, T1
Auboire, L1
Boutemy, J1
Constans, JM1
Le Gallou, T1
Busson, P1
Bienvenu, B1
Batlle, L1
Mattie, R1
Irwin, R1
Le Guellec, C1
Benz-de Bretagne, I1
Jonville-Bera, AP1
Tarfaoui, N1
Andres, CR1
Gendrot, C1
Jourdain, A1
Metzger, ML1
Weinstein, HJ1
Hudson, MM1
Billett, AL1
Larsen, EC1
Friedmann, A1
Howard, SC1
Donaldson, SS1
Krasin, MJ1
Kun, LE1
Marcus, KJ1
Yock, TI1
Tarbell, N1
Billups, CA1
Wu, J1
Link, MP1
Nizeica, V1
Collet, P1
Marotte, H1
Lagalla, G1
Logullo, F1
Di Bella, P1
Provinciali, L1
Ceravolo, MG1
ELLIOTT, FA1
de Carsalade, GY1
Achirafi, A1
Flageul, B1
Dabby, R1
Gilad, R1
Sadeh, M1
Lampl, Y1
Watemberg, N1
Gorson, KC1
Herrmann, DN1
Thiagarajan, R1
Brannagan, TH1
Chin, RL1
Kinsella, LJ1
Ropper, AH1
Clemmensen, OJ1
Andersen, KE1
Parkes, JD1
Calza, AM1
Schmied, E1
Harms, M1
Benoldi, D1
Mirizzi, S1
Zucchi, A1
Allegra, F1
Anderson, DJ1
Janoff, EN1
Diamond, S1
Dickinson, JA1
D'Elia, A1
Colella, C1
Contursi, R1
Pearce, J1
Kronschnabel, EF1
Saccabusi, E1
Burch, GE1
Giles, TD1
Reifenberg, E1
Fleischer, K1
Wieczorek, V1
Jung, H1
Leng-Lévy, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Risk-Adapted Therapy for Pediatric Hodgkin's Disease[NCT00145600]Phase 2296 participants (Actual)Interventional2000-03-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Correlation of Agreement Between Patient Cognitive Problems (Child + Teen) QoL and Parent Proxy Cognitive Problems (Child + Teen) QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy cognitive problems (child + teen) quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Interventionunits on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)77.6
Parent Completion of 2 Cycles of Chemotherapy (T2)75.7
Patient Completion of 4 Cycles of Chemotherapy (T3)78.9
Parent Completion of 4 Cycles of Chemotherapy (T3)74.3
Patient 3-6 Months After the Completion of Therapy (T5)80.8
Parent 3-6 Months After the Completion of Therapy (T5)76.3

Correlation of Agreement Between Patient Communication QoL and Parent Proxy Communication QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy communication quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Interventionunits on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)78.3
Parent Completion of 2 Cycles of Chemotherapy (T2)73.6
Patient Completion of 4 Cycles of Chemotherapy (T3)80.6
Parent Completion of 4 Cycles of Chemotherapy (T3)74.9
Patient 3-6 Months After the Completion of Therapy (T5)83.7
Parent 3-6 Months After the Completion of Therapy (T5)83.1

Correlation of Agreement Between Patient Emotional QoL and Parent Proxy Emotional QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy emotional quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Interventionunits on a scale (Mean)
Patient At Diagnosis (T1)68.4
Parent At Diagnosis (T1)62.3
Patient Completion of 2 Cycles of Chemotherapy (T2)70.7
Parent Completion of 2 Cycles of Chemotherapy (T2)64
Patient Completion of 4 Cycles of Chemotherapy (T3)74.1
Parent Completion of 4 Cycles of Chemotherapy (T3)65.7
Patient 3-6 Months After the Completion of Therapy (T5)78.5
Parent 3-6 Months After the Completion of Therapy (T5)77.1

Correlation of Agreement Between Patient Nausea QoL and Parent Proxy Nausea QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy nausea quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Interventionunits on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)60.7
Parent Completion of 2 Cycles of Chemotherapy (T2)58.6
Patient Completion of 4 Cycles of Chemotherapy (T3)59.7
Parent Completion of 4 Cycles of Chemotherapy (T3)57.7
Patient 3-6 Months After the Completion of Therapy (T5)75
Parent 3-6 Months After the Completion of Therapy (T5)78.9

Correlation of Agreement Between Patient Pain and Hurt QoL and Parent Proxy Pain and Hurt QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy pain and hurt quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Interventionunits on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)67.7
Parent Completion of 2 Cycles of Chemotherapy (T2)57.3
Patient Completion of 4 Cycles of Chemotherapy (T3)69.4
Parent Completion of 4 Cycles of Chemotherapy (T3)60.2
Patient 3-6 Months After the Completion of Therapy (T5)83.4
Parent 3-6 Months After the Completion of Therapy (T5)77

Correlation of Agreement Between Patient Peds QL4 (Composite) QoL and Parent Proxy Peds QL4 (Composite) QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy Peds QL4 (composite) quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Interventionunits on a scale (Mean)
Patient At Diagnosis (T1)76.2
Parent At Diagnosis (T1)72.4
Patient Completion of 2 Cycles of Chemotherapy (T2)74.2
Parent Completion of 2 Cycles of Chemotherapy (T2)69.3
Patient Completion of 4 Cycles of Chemotherapy (T3)77
Parent Completion of 4 Cycles of Chemotherapy (T3)70.6
Patient 3-6 Months After the Completion of Therapy (T5)84
Parent 3-6 Months After the Completion of Therapy (T5)80.7

Correlation of Agreement Between Patient PedsQL3 (Composite) QoL and Parent Proxy PedsQL3 (Composite) QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy PedsQL3 (composite) quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Interventionunits on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)72.4
Parent Completion of 2 Cycles of Chemotherapy (T2)68.3
Patient Completion of 4 Cycles of Chemotherapy (T3)72.7
Parent Completion of 4 Cycles of Chemotherapy (T3)67.6
Patient 3-6 Months After the Completion of Therapy (T5)78.1
Parent 3-6 Months After the Completion of Therapy (T5)77.6

Correlation of Agreement Between Patient Perceived Physical Appearance QoL and Parent Proxy Perceived Physical Appearance QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy perceived physical appearance quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Interventionunits on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)77.5
Parent Completion of 2 Cycles of Chemotherapy (T2)71.9
Patient Completion of 4 Cycles of Chemotherapy (T3)77.6
Parent Completion of 4 Cycles of Chemotherapy (T3)71.2
Patient 3-6 Months After the Completion of Therapy (T5)78.4
Parent 3-6 Months After the Completion of Therapy (T5)80.5

Correlation of Agreement Between Patient Physical QoL and Parent Proxy Physical QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy physical quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Interventionunits on a scale (Mean)
Patient At Diagnosis (T1)77.2
Parent At Diagnosis (T1)73.9
Patient Completion of 2 Cycles of Chemotherapy (T2)72.3
Parent Completion of 2 Cycles of Chemotherapy (T2)65.4
Patient Completion of 4 Cycles of Chemotherapy (T3)74.7
Parent Completion of 4 Cycles of Chemotherapy (T3)66.5
Patient 3-6 Months After the Completion of Therapy (T5)84.5
Parent 3-6 Months After the Completion of Therapy (T5)78.6

Correlation of Agreement Between Patient Procedural Anxiety QoL and Parent Proxy Procedural Anxiety QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy procedural anxiety quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Interventionunits on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)71.3
Parent Completion of 2 Cycles of Chemotherapy (T2)70.3
Patient Completion of 4 Cycles of Chemotherapy (T3)73.8
Parent Completion of 4 Cycles of Chemotherapy (T3)63.2
Patient 3-6 Months After the Completion of Therapy (T5)78.5
Parent 3-6 Months After the Completion of Therapy (T5)72.7

Correlation of Agreement Between Patient Psychosocial QoL and Parent Proxy Psychosocial QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy psychosocial quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Interventionunits on a scale (Mean)
Patient At Diagnosis (T1)75.7
Parent At Diagnosis (T1)71.3
Patient Completion of 2 Cycles of Chemotherapy (T2)75.1
Parent Completion of 2 Cycles of Chemotherapy (T2)71.1
Patient Completion of 4 Cycles of Chemotherapy (T3)77.5
Parent Completion of 4 Cycles of Chemotherapy (T3)72.3
Patient 3-6 Months After the Completion of Therapy (T5)83.1
Parent 3-6 Months After the Completion of Therapy (T5)80.7

Correlation of Agreement Between Patient School QoL and Parent Proxy School QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy school quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Interventionunits on a scale (Mean)
Patient At Diagnosis (T1)69.6
Parent At Diagnosis (T1)66.2
Patient Completion of 2 Cycles of Chemotherapy (T2)67.2
Parent Completion of 2 Cycles of Chemotherapy (T2)66.7
Patient Completion of 4 Cycles of Chemotherapy (T3)69
Parent Completion of 4 Cycles of Chemotherapy (T3)66.7
Patient 3-6 Months After the Completion of Therapy (T5)78.6
Parent 3-6 Months After the Completion of Therapy (T5)76.5

Correlation of Agreement Between Patient Social QoL and Parent Proxy Social QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy social quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Interventionunits on a scale (Mean)
Patient At Diagnosis (T1)87.2
Parent At Diagnosis (T1)83
Patient Completion of 2 Cycles of Chemotherapy (T2)87.2
Parent Completion of 2 Cycles of Chemotherapy (T2)81.4
Patient Completion of 4 Cycles of Chemotherapy (T3)88.2
Parent Completion of 4 Cycles of Chemotherapy (T3)82.2
Patient 3-6 Months After the Completion of Therapy (T5)91.5
Parent 3-6 Months After the Completion of Therapy (T5)85.8

Correlation of Agreement Between Patient Treatment Anxiety QoL and Parent Proxy Treatment Anxiety QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy treatment anxiety quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Interventionunits on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)84.1
Parent Completion of 2 Cycles of Chemotherapy (T2)72.8
Patient Completion of 4 Cycles of Chemotherapy (T3)82.8
Parent Completion of 4 Cycles of Chemotherapy (T3)71.1
Patient 3-6 Months After the Completion of Therapy (T5)82.1
Parent 3-6 Months After the Completion of Therapy (T5)77.6

Correlation of Agreement Between Patient Worry QoL and Parent Proxy Worry QoL at Multiple Time Points.

Assess and compare the patient reported and parent proxy worry quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Interventionunits on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)64.5
Parent Completion of 2 Cycles of Chemotherapy (T2)64.5
Patient Completion of 4 Cycles of Chemotherapy (T3)64.7
Parent Completion of 4 Cycles of Chemotherapy (T3)64.7
Patient 3-6 Months After the Completion of Therapy (T5)67.1
Parent 3-6 Months After the Completion of Therapy (T5)68.6

Event-free Survival Probability by Risk Group

Event-free survival (EFS) is based on the time from protocol enrollment to the occurrence of first event (relapse or progressive disease, subsequent malignancy, or death from any cause). Patients not experiencing an event are censored at their last follow-up date. Event-free Survival Probability will be estimated by Kaplan-Meier (KM) method with a 95% confidence interval calculated using the Greenwood's formula. (NCT00145600)
Timeframe: Median 6.4 year follow-up

Interventionprobability of 5 yr. event free survival (Number)
Favorable Risk0.886
Intermediate Risk0.844
Unfavorable Risk, Group 10.667
Unfavorable Risk, Group 20.793

Event-free Survival Probability by Risk Group at 10-year Follow-Up

Event-free survival (EFS) is based on the time from protocol enrollment to the occurrence of first event (relapse or progressive disease, subsequent malignancy, or death from any cause). Patients not experiencing an event are censored at their last follow-up date. Event-free Survival Probability will be estimated by Kaplan-Meier (KM) method with a 95% confidence interval calculated using the with Greenwood's formula. (NCT00145600)
Timeframe: 10-year follow-up after protocol enrollment

Interventionprobability 10 yr. event free survival (Number)
Favorable Risk0.874
Intermediate Risk0.844
Unfavorable Risk, Group 10.667
Unfavorable Risk, Group 20.785

Trials

6 trials available for prednisone and Neuralgia

ArticleYear
Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma.
    JAMA, 2012, Jun-27, Volume: 307, Issue:24

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Disease-Free Su

2012
Influence of early high-dose steroid treatment on Bell's palsy evolution.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bell Palsy; Dose-Response Rela

2002
[Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
    Acta leprologica, 2003, Volume: 12, Issue:3

    Topics: Adolescent; Adult; Erythema Nodosum; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppr

2003
ACTH versus prednisone and placebo in herpes zoster treatment.
    Clinical and experimental dermatology, 1984, Volume: 9, Issue:6

    Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cosyntropin; Double-Blind Method; Female; Herpes

1984
Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy.
    International journal of dermatology, 1991, Volume: 30, Issue:4

    Topics: Acute Disease; Acyclovir; Administration, Oral; Aged; Combined Modality Therapy; Female; Herpes Zost

1991
[Controlled clinical trial a gastroprotective steroid (prednisone + xylamide)].
    Minerva medica, 1972, Sep-19, Volume: 63, Issue:65

    Topics: Amides; Arthritis, Rheumatoid; Asthma; Benzoates; Bronchitis; Chronic Disease; Drug Combinations; Ev

1972

Other Studies

22 other studies available for prednisone and Neuralgia

ArticleYear
Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry.
    Annals of hematology, 2014, Volume: 93, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem

2014
[Malignant lymphoma in a perineural spreading along trigeminal nerve, which developed as trigeminal neuralgia].
    Rinsho shinkeigaku = Clinical neurology, 2014, Volume: 54, Issue:8

    Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop

2014
Idiopathic hypertrophic pachymeningitis presenting with occipital neuralgia.
    African health sciences, 2015, Volume: 15, Issue:1

    Topics: Cranial Nerve Diseases; Cyclophosphamide; Dura Mater; Headache; Humans; Immunosuppressive Agents; Ma

2015
A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report.
    PM & R : the journal of injury, function, and rehabilitation, 2016, Volume: 8, Issue:3

    Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Thera

2016
A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions?
    Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:8

    Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; ATP Binding Cassette T

2012
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
    Annals of hematology, 2013, Volume: 92, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acid

2013
TREATMENT OF HERPES ZOSTER WITH HIGH DOSES OF PREDNISONE.
    Lancet (London, England), 1964, Sep-19, Volume: 2, Issue:7360

    Topics: Geriatrics; Herpes Zoster; Herpes Zoster Ophthalmicus; Humans; Neuralgia; Prednisone; Prognosis

1964
Acute steroid responsive small-fiber sensory neuropathy: a new entity?
    Journal of the peripheral nervous system : JPNS, 2006, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Biopsy; Dermatologic Surgical Procedures; Female; Glucocorticoids; Humans; Immuno

2006
Non-length dependent small fibre neuropathy/ganglionopathy.
    Journal of neurology, neurosurgery, and psychiatry, 2008, Volume: 79, Issue:2

    Topics: Adult; Aged; Autonomic Nervous System; Biopsy; Cell Count; Extremities; Facial Pain; Female; Follow-

2008
Diseases of the central nervous system. Relief of pain: headache, facial neuralgia, migraine, and phantom limb.
    British medical journal, 1975, Oct-11, Volume: 4, Issue:5988

    Topics: Analgesics; Aspirin; Carbamazepine; Ergotamines; Facial Neuralgia; Giant Cell Arteritis; Headache; H

1975
Systemic corticosteroids do not prevent postherpetic neuralgia.
    Dermatology (Basel, Switzerland), 1992, Volume: 184, Issue:4

    Topics: Female; Follow-Up Studies; Herpes Zoster; Humans; Male; Middle Aged; Neuralgia; Prednisone; Random A

1992
Herpes zoster infection in a patient on methotrexate given prednisone to prevent post-herpetic neuralgia.
    Annals of internal medicine, 1987, Volume: 107, Issue:5

    Topics: Aged; Female; Herpes Zoster; Humans; Methotrexate; Neuralgia; Prednisone; Virus Activation

1987
Postherpetic neuralgia. Prevention and treatment.
    Postgraduate medicine, 1987, Volume: 81, Issue:4

    Topics: Aged; Herpes Zoster; Humans; Middle Aged; Nerve Block; Neuralgia; Prednisone; Stellate Ganglion; Tri

1987
Should we treat herpes zoster with corticosteroid agents?
    The Medical journal of Australia, 1986, Mar-31, Volume: 144, Issue:7

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Carbamazepine; Child; Child, Preschool; Herpes Zos

1986
Postherpetic neuralgia.
    British medical journal, 1973, Mar-17, Volume: 1, Issue:5854

    Topics: Herpes Zoster; Humans; Neuralgia; Prednisone

1973
Orbital apex syndrome due to sinus infection.
    The Laryngoscope, 1974, Volume: 84, Issue:3

    Topics: Abscess; Anti-Bacterial Agents; Blepharoptosis; Blindness; Cellulitis; Conjunctiva; Cornea; Diagnosi

1974
[Clinical trial of a drug with steroid activity combined with a gastroprotective substance].
    Minerva medica, 1972, Sep-08, Volume: 63, Issue:62

    Topics: Adult; Amides; Benzoates; Drug Combinations; Drug Tolerance; Gastric Juice; Glutamine; Humans; Infla

1972
Cardiac causalgia.
    Archives of internal medicine, 1970, Volume: 125, Issue:5

    Topics: Adult; Angina Pectoris; Arthritis; Body Temperature; Diagnosis, Differential; Electrocardiography; F

1970
[The cervico-vertebral facial paresis].
    Zeitschrift fur arztliche Fortbildung, 1967, May-15, Volume: 61, Issue:10

    Topics: Adult; Cervical Vertebrae; Facial Paralysis; Female; Humans; Male; Middle Aged; Neck; Neuralgia; Ost

1967
[On the carotid pain. Giant cell arteritis and Hilger's syndrome].
    Zeitschrift fur Laryngologie, Rhinologie, Otologie und ihre Grenzgebiete, 1968, Volume: 47, Issue:3

    Topics: Aged; Arteritis; Carotid Artery Diseases; Diagnosis, Differential; Female; Humans; Middle Aged; Migr

1968
[On the clinical picture of the neuralgic amyotrophy (Syndrom of Parsonage and Turner)].
    Der Nervenarzt, 1965, Volume: 36, Issue:7

    Topics: Adult; Blood Sedimentation; Cerebrospinal Fluid; Electromyography; Female; Humans; Male; Muscular At

1965
[The antalgic and antirheumatic action of a neurotropic vitamin, aspirin and corticoid association].
    Semaine therapeutique, 1965, Volume: 41, Issue:9

    Topics: Analgesics; Arthritis, Rheumatoid; Aspirin; Humans; Neuralgia; Prednisone; Vitamin B Complex

1965